Innovent Biologics, Inc. (IVBXF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. De-Chao Yu Ph.D. | Co-Founder, Chairman & CEO | 4.55M | -- | 1964 |
| Mr. Hao Xi Ede | Executive Director & Fund Managing Partner | 961.25k | -- | 1959 |
| Dr. Yong Jun Liu M.D., Ph.D. | President | -- | -- | 1969 |
| Ms. Fei You | Chief Financial Officer | -- | -- | 1979 |
| Ms. Vivian Zhang | Chief People Officer & GM | -- | -- | -- |
| Mr. Min Liu | Chief Commercial Officer | -- | -- | -- |
| Mr. Dongming Wang | Senior Vice President | -- | -- | -- |
| Mr. Blake Salisbury | Senior Vice President | -- | -- | -- |
| Dr. Hui Zhou Ph.D. | Senior Vice President | -- | -- | -- |
| Dr. Nageatte Ibrahim | Oncology Chief Medical Officer | -- | -- | -- |
Innovent Biologics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 4,872
Description
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available